Introduction
The estrogen receptors (ERs) are ligand-dependent nuclear receptors that contain a DNA binding domain, ligand binding domain, an N-terminal transcriptional activating function AF-1 and a C-terminal AF-2 (1). There are two subtypes called ERα and ERβ which can either form homodimers or heterodimers to transactivate responsive genes in the presence of E2. While the ERα has a strong ligand independent AF-1 region, the ERβ AF-1 function is weaker (2) and mediates a dominant negative effect on ERα as a result of an N-terminal repressor function (3) .
ChIP on chip analysis suggests that there is considerable overlap in DNA response element binding between the two receptors (4). ERβ activity is not only cell type-dependent but also enhancer sequence and ligand-dependent (5) . Several groups have demonstrated that ectopic expression of the ERβ in ERα+ breast cancer cells results in growth inhibition (6, 7) and prevents xenograft formation in nude mice in response to E2 (7) . ERβ regulates gene transcription in an E2-independent and dependent manner with downstream effects impacting on cell cycle progression (8, 9) . Overexpression of ERβ can activate p21 and p27 expression causing a G2 accumulation (3) . Cyclin D1 is positively regulated by the ERα and negatively regulated by the ERβ in the presence of E2 (7) .
In the normal human and rodent mammary gland the ERβ is expressed at higher levels than the ERα. This ratio is typically reversed in ER+ breast cancer (10) although many breast cancers continue to express low levels of ERβ. Reduced ERβ expression in ER+ breast cancer cells is due in part to promoter methylation (11) .
The standard of endocrine treatment for estrogen receptor positive (ER+) breast cancer is the selective estrogen receptor modulator (SERM), Tamoxifen (TAM). Unfortunately, the vast 4 majority of responsive tumors eventually develop SERM resistance. TAM-resistant (Tam-R) cell lines remain sensitive to growth inhibition by selective ER down-regulators (SERDs) including fulvestrant (ICI 182,780) (12) (13) (14) (15) . About half of patients respond to second-line endocrine therapy including aromatase inhibitors and fulvestrant (16) , however fulvestrant-resistant cells emerge (17) representing the limits of current endocrine therapy.
SERM resistance can be either intrinsic to a subpopulation of breast cancer cells within a tumor or can be acquired (18, 19) . Typically, SERM resistance is not associated with loss the ER (estimated at less than 25%)(20). SERM resistance is complex and involves changes in intracellular signaling through growth factors or activated oncogenes that is implicated in the ligand-independent activation of the ER (18, 21) .
TAM is a pure antagonist at the ERβ (22) and some reports have shown a correlation between lack of ERβ expression and de novo SERM resistance (23) while others found that SERM-resistant tumors have increased ERβ mRNA expression (24) . Derivatives of MCF-7 ER+ breast cancer cells have been selected for SERM/SERD resistance and demonstrate a net decrease in the expression of the ERα but not ERβ (25) . One such cell line called LCC9 was derived from MCF-7 cells after long term culture in the presence of fulvestrant and displays cross-resistance to TAM (17) .
In previous work we have designed and synthesized new ligands that preferentially activate the ERβ (26) . The structure of L17 is based on the ABCD-ring structure of E2 but lacks the B ring. In the current study, we have investigated the impact of L17 and a second ERβ 
Materials and Methods

Cell lines and cell culture
MCF-7/LCC1 and MCF-7/LCC9 and MCF-7CL parental cells (28) were obtained from Dr.
Robert Clarke, Georgetown University, at low passage and were routinely cultured in DMEM (with or without phenol red) containing 5% unstripped or dextran-charcoal stripped FBS (CSS).
The genetic relationship of the three cell lines with the original MCF-7 cell line was confirmed by DNA fingerprinting using genetic markers at nine different loci (CSF1PO, TPOX, TH01, vWA, D16S539, D7S820, D13S317, D5S818, and the Y chromosome-specific amelogenin in the Clarke lab. Cells were passaged a maximum of 8 times from the point of receipt. Markers were not retested although SERM/SERD-resistance of LCC9 cells was reconfirmed (supplementary data). MCF-7 cells (denoted MCF-7PL) were originally obtained from the ATCC. They have not been retested for lineage markers but continue to express the luminal markers ERα, E-cadherin, pS2 and CK18. The MCF-7 (rTA tet-ON ERβ1) subclone was obtained from Dr. Leigh Murphy, University of Manitoba, and were derived from a clone of MCF-7 cells stably expressing reverse tetracycline transactivator (clone 89 rTA) transfected with doxycycline-inducible His-Xpress-ERβ1 expression (tagged-ERβ1) (29 and refs therein) . These clones were not tested for genetic markers prior to or after receipt but were used exclusively for ChIP analysis after acute treatment with ligands. All cells were shown to be free of Mycoplasma contamination by PCR. 
Immunoblot
Proteins were separated using SDS-PAGE and transferred to PVDF membranes (Millipore, Etobicoke, ON). Immunoreactive bands were detected using substrate (Millipore) and quantified by densitometry using Image J v1.43.
Chromatin immunoprecipitation
ChIP assays were performed using a ChIP assay kit (Upstate Biotechnology, Charlottesville, VA) according to the manufacturer's instructions with some modifications. Cells were treated with vehicle, 10 nM E2, L17, or WAY for 30 min (ER ChIP) or 15 min (RIP140/SRC-3 ChIP).
Chromatin was cross-linked with 1% formaldehyde then sonicated and protein-DNA complexes were immunoprecipitated with anti-ERα, anti-ERβ, anti-RIP140, anti-SRC-3, normal rabbit immunoglobulin G (IgG) or no antibody (input) at 4°C overnight. Cross-links were reversed at 65°C for 4 h. DNA was purified by phenol/chloroform extraction, precipitated and subjected to PCR analysis. PCR primer sequences were the same as those used in qRT-PCR. 5μl of DNA (no antibody) was used for the input PCR reaction. Products were run on a 1% agarose gel and Figure   S1 ).
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We next determined the effects of E2 and our novel ligand, L17, on proliferation of MCF-7 cells and LCC9 cells. We chose to use MCF-7PL cells since they express levels of the ERβ comparable to LCC9 cells and therefore serve as a more appropriate comparison than MCF-7CL cells. The results in Figure 1C demonstrate that E2 increased MCF-7 viable cell numbers in a concentration-dependent manner while L17 had no significant effect. In contrast, E2 had little overall effect on LCC9 proliferation consistent with a previous report (30) . Remarkably, L17 induced a dose-dependent decrease in viable cell numbers within 3 days which approached 40% within 5 days ( Figure 1D ). WAY and L17 had a similar growth inhibitory effect on LCC9 cells at 10nM ( Figure 1E ). In order to verify that growth inhibition induced by L17 was mediated through the ERβ, we treated LCC9 cells infected with a non-targeting retrovirus (shNT) or pSUPER-ERβ shRNA (shERβ) (31) with L17 or vehicle. After 5 days, decreased proliferation was observed in L17-treated shNT-infected cells while shERβ expression completely prevented growth inhibition ( Figure 1F ). Verification of ERβ knockdown is shown in Figure 1G . These results are consistent with L17 signaling in an ERβ-dependent manner to inhibit LCC9 cell proliferation. Knockdown of ERβ using siRNA showed that the L17-mediated decrease in Bcl-2 expression in LCC9 cells was ERβ-dependent ( Figure 4C,D) . Thus, activation of the ERβ, especially by ERβ-preferential agonists, has opposite effects on Bcl-2 expression in LCC9 and MCF-7 cells that may be a consequence of the high ERβ:ERα ratio in LCC9 cells.
ERβ agonists inhibit G1 and S phase exit in LCC9 cells
ERβ agonists recruit both the ERβ and ERα to the Bcl-2 estrogen response element:
The ability of ERβ ligands to reduce Bcl-2 expression in LCC9 cells might be the result of the association of ERβ agonist-bound homodimers or ERβ/ERα heterodimers to the Bcl-2 ERE. To address this question we performed a chromatin immunoprecipitation (ChIP) analysis with antibodies against ERα and ERβ following a 1hr exposure to each ligand. PCR using primers adjacent to Bcl-2 ERE in exon 2 (36) . We used the pS2 gene as a second ERE-containing E2-responsive gene since the ERβ had previously been shown to interact with its promoter region Figure 5A ,B) which corresponded to weak induction (E2) or significant inhibition of expression (L17 and WAY) following a 1hr treatment ( Figure 5F ). Although all three ligands also recruited both the ERα and ERβ in MCF-7 cells ( Figure 5C,D) , only E2 strongly increased 13 pS2 mRNA ( Figure 5F ).
We also analyzed mRNA levels 24hr after treatment to assess the longer term effects of ligand activation on transcript levels. Both Bcl-2 and pS2 mRNA remained elevated after 24hr in MCF-7 cells treated with E2 while the reduction in levels became less significant in L17 and WAY-treated MCF-7 and LCC9 cells and in E2-treated LCC9 cells ( Figure 5G ). pS2 transcripts maintained a similar pattern of expression after 24hrs although a small rebound in pS2 mRNA was observed in L17-treated cells, possibly due to receptor desensitization which could alleviate repression ( Figure 5H ). (38) . Consistent with this, the ERα protein was rapidly downregulated following E2-mediated transactivation ( Figure 5J ). L17 has a low level of ERα binding activity and resulted in a weak reduction in the ERα protein. The ERβ protein was only slightly reduced by both E2 and WAY, and L17 had no effect. This is consistent with the overall lack of transcriptional activation by the ERα in the presence of WAY and L17 as well as when all ligands bound to the ERβ.
Chloroquine converts L17/WAY-induced autophagy to apoptosis. Chloroquine (CQ)
prevents the acidification of lysosomes to repress autophagy (39) . Since WAY and L17 reduced Bcl-2 and increased levels of LC3-II in LCC9 cells, we tested the possibility that CQ might convert this autophagic response to cell death. Figure 6A shows that a 5 day treatment with 33μM CQ to E2-free cultures caused an approximate 20% decrease in LCC9 cells and 35% in MCF-7 cells compared to vehicle-treated cells ( Figure 6B ). To confirm that the effects of CQ in the presence of L17 were ERβ-dependent, LCC9 cells infected with shERβ or control shNT were treated with L17, WAY or vehicle in the presence or absence of CQ. Figure 6C shows that knockdown of ERβ prevented the effects of CQ both in the presence and absence of the ERβ ligands. This result suggests that the ERβ may act as both a ligand-dependent and independent mediator of autophagy. 
Discussion
Previous studies have demonstrated that overexpression of the ERβ in MCF-7 breast cancer cells can inhibit cell growth in the presence of E2 (29) and prevent xenograft tumor formation (7). In transfected HeLa cells the ERβ alone is unable to activate the transcription of the cyclin D1 gene in the presence of E2 and prevents E2-activation of cyclin D1 in the presence of coexpressed ERα (40) . Although ERβ activation has anti-proliferative effects, the majority of human ER+ breast tumors do not express high levels of ERβ relative to ERα at diagnosis. Remarkably, cell lines with acquired resistance to SERMs express an increased ratio of ERβ to ERα (25) .
In this study we found that L17 and WAY had modulatory effects on cell cycle proteins 
